 Home > Active Ingredient News > Antitumor Therapy > Eur Radiol: Can gadolinium disodium-enhanced MRI-enhanced postoperative prognostic evaluation of liver cancer be applied to multicenters?

Eur Radiol: Can gadolinium disodium-enhanced MRI-enhanced postoperative prognostic evaluation of liver cancer be applied to multicenters?

 Last Update: 2021-03-20
 Source: Internet
 Author: User

Tags

number 3 chain

1 3 dibromopropane

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hepatocellular carcinoma (HCC) has always been an important global health problem, with an increasing incidence worldwide.

Multi-phase CT and MRI examinations have been proved by many studies to play an important role in the detection, characterization and staging of liver cancer.

Recently, a study published in the journal European Radiology clarified the clinical and histopathological prognostic factors of patients with multicenter multiple hepatocellular carcinoma (HCC) after surgical resection, and evaluated specific imaging-related factors (including arterial Apparent enhancement (APHE) and gadoxetate disodium enhance the LI-RADS category of each lesion on MRI) can provide additional prognostic information when diagnosing multicenter HCC.

This retrospective study included a total of 120 multicentric liver cancer lesions in 54 patients who were diagnosed with liver cancer by surgical resection in a tertiary hospital between 2009 and 2014.

Microvascular infiltration (MVI) (p = 0.

Figure 1 Kaplan-Meier survival curve based on microvascular infiltration (MVI) and the number of multicentric HCC.

Figure 2 Kaplan-Meier survival curve of multicentric HCC patients with two lesions based on LI-RADS classification and APHE.

MVI and 3 or more liver cancers are independent predictors of shorter DFS after surgical resection of multicentric HCC cancer.

Original source:

Seung-Seob Kim,Sunyoung Lee,Myeong-Jin Kim.

Seung-Seob Kim, Sunyoung Lee, Myeong-Jin Kim.
et al.
Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
PMID:33146795DOI: org/10.
1007/s00330-020-07419-y">10.
1007/s00330-020-07419-yorg/10.
1007/s00330-020-07419-y"> 10.
1007/s00330-020 -07419-y Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.